Nishida, Toshihiko
,
Okumura, Yasuo
Yokoyama, Katsuaki
Matsumoto, Naoya
Tachibana, Eizo
Kuronuma, Keiichiro
Oiwa, Koji
Matsumoto, Michiaki
Kojima, Toshiaki
Hanada, Shoji
Nomoto, Kazumiki
Sonoda, Kazumasa
Arima, Ken
Kogawa, Rikitake
Takahashi, Fumiyuki
Kotani, Tomobumi
Ohkubo, Kimie
Fukushima, Seiji
Itou, Satoru
Kondo, Kunio
Chiku, Masaaki
Ohno, Yasumi
Onikura, Motoyuki
Hirayama, Atsushi
Funding for this research was provided by:
Bayer Yakuhin Ltd
Article History
Received: 5 March 2019
Accepted: 31 May 2019
First Online: 10 June 2019
Compliance with ethical standards
:
: Dr. Okumura has accepted remuneration from Daiichi-Sankyo; Dr. Hirayama has received research funding from Bayer Healthcare, Daiichi-Sankyo, Otsuka Pharmaceutical, Astellas Pharma, Eisai, Sumitomo Dainippon Pharma, MSD, Nihon Medi-Physics, Bristol-Meyers Squibb, Boehringer Ingelheim, Pfizer, Boston Scientific Corporation, Hokushin Medical, and has accepted remuneration from Bayer Healthcare, Daiichi-Sankyo, Eisai, Bristol-Meyers Squibb, Astellas Pharma, Sanofi, and Takeda Pharmaceutical; Dr Matsumoto has received research funding from Daiichi-Sankyo, Otsuka Pharmaceutical, and Sumitomo Dainippon Pharma, and has accepted remuneration from Nihon Medi-Physics, FUJIFILM RI Pharma, and Biosensors Interventional Technologies Japan.